From Pitch Deck to Due Diligence: Managing Sensitive Information in a Biotech Fundraise

TL;DR

A biotech fundraise can start with a pitch deck and high-level company information shared over email. As investor conversations progress, however, diligence may extend into intellectual property, financial information, technical research, regulatory materials and other confidential information — the point at which many companies start looking at a biotech data room instead of ad hoc file sharing.

That creates a different problem from simply sending investors more files.

The company and its advisors still need to decide what information is appropriate to disclose and when. But once that decision has been made, another set of questions emerges: Who should have access? What should recipients be allowed to do with the information? How long should that access remain available? And what visibility should the company retain after sharing?

Those are information-management decisions, and they become increasingly important as diligence gets deeper.

How should biotech companies manage sensitive information during investor due diligence?

There is no universal rule for which documents a biotech company should disclose to investors or at what point in a fundraise. Once the company and its advisors decide that sensitive information should be shared, however, the process should make it clear who can access it, what they can do with it, how long that access remains available and what happens after it is shared.

A useful way to think about this is through four questions:

This framework does not determine what your company should disclose. Instead, it helps you manage the information after the disclosure decision has been made.

Why biotech diligence can create a different information-sharing problem

Investor due diligence is not limited to financial statements and corporate records.

The World Intellectual Property Organization (WIPO) describes IP due diligence as an audit of a company's intangible assets — including patents, trade secrets and other intellectual property — that may be conducted by potential investors, partners or buyers when a venture is raising capital. WIPO notes that trade secrets can cover technical information such as manufacturing processes and pharmaceutical test data, provided the information meets the relevant requirements for trade-secret protection.

The implication is not that every biotech company must place the same scientific or IP documents into its investor data room.

It is that a pitch deck, a financial forecast and confidential technical information may carry very different levels of sensitivity. Treating all three with exactly the same sharing settings may therefore make little sense. For a wider look at the pressures shaping this sector, see our guide to biotech fundraising trends, challenges and data security.

The right disclosure strategy will depend on your company. The information controls around that strategy should be just as deliberate.

Think about sensitivity, not only folders

Data-room advice often starts with folder structures: Corporate, Financial, IP, Regulatory, Clinical, Commercial.

That can be useful for organization, but folders alone do not tell you how information should be handled.

Consider two files in the same folder. One might already contain information that has been widely circulated to prospective investors. Another might contain highly confidential technical details that the company only intends to share with a small group conducting deeper diligence.

Their location might be similar. Their sensitivity might not be.

A better starting point is to ask how sensitive the information is in your specific context.

These categories are illustrative, not disclosure recommendations. The sensitivity of any particular document and its appropriate treatment should be determined by the company with the relevant internal and professional advisors.

The broader information-security principle is well established. NIST's guidance on information exchanges says information shared between organizations should receive protection commensurate with its risk before, during and after the exchange.

Access can change as diligence progresses

Investor diligence is not one event.

A company might initially have conversations with a broad group of prospective investors, then move into more detailed discussions with a smaller set of parties. Specialist advisors or technical diligence participants may become involved. Some investors may leave the process while others request additional information.

That means access does not necessarily need to remain static.

WIPO's 2026 guidance on using virtual data rooms for IP investment specifically recommends need-to-know permissions, expiring invitations, watermarking, and logging downloads and interactions when managing confidential IP information in a VDR.

The useful capability here is not predicting which scientific document belongs at which stage. It is being able to change access without rebuilding the entire sharing process.

Decision 1: Who actually needs access?

Once information has been approved for sharing, the next question is who needs to see it.

Different investors may be at different stages of the process. A prospective investor evaluating the opportunity may not need the same access as a lead investor engaged in detailed diligence. External advisors or specialists may need access to a specific subset of information rather than the whole room.

If your diligence process requires those distinctions, your data room should support them. Digify virtual data rooms support data-room, group and granular permissions, allowing owners to control access for different recipients rather than applying a single permission model to everyone.

The principle is simple:

Decide who should receive the information first. Then configure the room accordingly.

Decision 2: Does the recipient need a downloadable copy?

There is an important difference between allowing someone to see a document and allowing them to take a copy away.

For ordinary collaboration, downloading a file may be expected. For more sensitive external sharing, the decision deserves more thought. Ask:

• Does the recipient simply need to review the information?
• Do they need to print it?
• Do they need a PDF copy?
• Do they need the original file?
• Would view-only access satisfy the purpose of the disclosure?

Digify virtual data rooms include print and download permissions alongside granular access controls and dynamic watermarking.

This does not mean downloads are bad. In some situations, recipients may genuinely need them. The more useful question is:

Those are different decisions.

Decision 3: How long should access remain available?

Fundraising processes change. An investor may decide not to continue. A diligence workstream may finish. An advisor's involvement may end. A document may be superseded by a newer version.

Granting someone access once does not necessarily mean they need it forever. That is why expiry and revocation matter. Digify data rooms support data-room and guest access expiry as part of the platform's permission controls.

The practical approach is to treat access as something that has a lifecycle:

1. 1Grant access. Give the recipient the permission level the disclosure decision calls for.
2. 2Review. Check who still has access as the process moves forward.
3. 3Adjust if needed. Expand or narrow access as the diligence relationship changes.
4. 4Expire or revoke when no longer required. Close access rather than leaving it open by default.

This becomes especially useful when several investors are moving through diligence at different speeds.

Decision 4: What should you know after information is shared?

Document activity can provide useful context during a fundraise, but it needs to be interpreted carefully.

Seeing that an investor opened a document does not prove that they intend to invest. Spending more time on a page does not automatically indicate conviction. Activity data is a signal, not mind-reading. What it can provide is visibility. For example:

• Has the information been accessed?
• Which documents are being reviewed?
• Are recipients returning to particular materials?
• Has the latest information actually been opened?

Digify data rooms include analytics and an activity log for this purpose. Used appropriately, that information can give your fundraising team additional context when deciding where follow-up may be helpful.

What controlled disclosure looks like in a real fundraising process

The point is not that every biotech or medtech company should copy StratifiCare's exact workflow. It illustrates the underlying pattern: sensitive information is shared, access is controlled, activity provides additional context, and access can end when it is no longer required.

When does a biotech fundraise actually need a VDR?

A virtual data room is not automatically necessary the moment a company starts fundraising. For early conversations involving a small number of relatively non-sensitive materials, ordinary file sharing may be sufficient. The need for a VDR becomes stronger as the external-sharing requirements become more demanding.

Virtual data rooms are commonly used for startup fundraising, buyer/seller due diligence, IP licensing and other workflows involving confidential external information. Digify's VDR supports permissions, group access, print and download controls, dynamic watermarking, analytics and access expiry within that environment.

The dividing line, therefore, is not simply "we are a biotech company, so we need a VDR." A better question is:

A practical controlled-disclosure workflow

You do not need a complicated framework to apply these ideas. Before sharing a sensitive document, work through these decisions.

Before sharing

1. 1Confirm that the information has been approved for disclosure. The data room should enforce your disclosure strategy, not create it. Make sure the relevant people inside the company have decided that the information is appropriate to share.
2. 2Consider its sensitivity. A widely circulated fundraising deck and confidential technical information may deserve different controls.
3. 3Identify who actually needs access. Think in terms of recipients or groups rather than opening everything to everyone involved in the fundraise.
4. 4Decide what recipients need to do with it. Determine whether viewing is sufficient or whether print or download access is genuinely required.
5. 5Decide how long access should remain available. For information that only needs to be available temporarily, consider an expiry point.

During diligence

6. 6Adjust access as the process changes. Investor participation and diligence requirements evolve. Permissions should be able to evolve with them.
7. 7Keep current information available. A controlled repository is more useful when the documents investors see are the versions the company actually wants them reviewing.
8. 8Use activity as context, not certainty. Document engagement can help inform follow-up, but should not be treated as proof of investor intention.

When access is no longer required

9. 9Revoke access or allow it to expire. Do not leave access open simply because it was once necessary.
10. 10Maintain the relevant activity record. A clear history of what was accessed and by whom can make the diligence process easier to understand internally.

Managing disclosure without making diligence harder

Good information control should not prevent investors from doing their work. Investors still need enough information to evaluate the company. Founders still want diligence to move efficiently. Advisors and specialists need access to the materials relevant to their role.

The goal is not to add restrictions for the sake of security. It is to make access deliberate: the right recipient, the appropriate permissions, for as long as access is needed, with enough visibility for the company to understand what happened after sharing.

That becomes increasingly valuable when a biotech fundraise moves beyond the pitch deck and into sensitive IP, scientific, financial or regulatory information. Digify provides a modern virtual data room and secure document-sharing environment for managing those controls, including granular permissions, download restrictions, dynamic watermarking, expiry and activity tracking — without requiring teams to treat every document or recipient the same way.

Frequently Asked Questions